QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Reference Member State (RMS) in EU Regulatory Affairs

Test your understanding of the concepts covered by Reference Member State (RMS) in EU Regulatory Affairs.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A serious safety signal emerges for a DCP product. Which statement best reflects the RMS's role?

The RMS only forwards the signal and cannot contribute to the scientific assessment The RMS should integrate the evidence into the assessment and coordinate the regulatory process with CMSs The RMS automatically confirms causality when a plausible mechanism exists The RMS alone decides whether the QPPV has complied with pharmacovigilance obligations

Question 2 of 10 Which data model is most appropriate for an MRP/DCP product in a regulatory information system?

A single field stating 'EU authorised' Only the MAH name and the date of first approval Procedure number, authorisation route, RMS, CMSs, product information, variations, referrals and relevant restrictions Only the country where the product is manufactured

Question 3 of 10 Under what general circumstance can disagreement during an MRP or DCP progress toward an Article 29(4) referral?

Whenever the applicant dislikes a CMS comment Whenever the RMS and one CMS have different scientific preferences, regardless of risk When Member States fail to reach agreement on grounds of a potential serious risk to public health after the applicable coordination process Whenever a product has more than one CMS

Question 4 of 10 A safety assessment supports adding a warning across several Member States for an MRP/DCP product. What should the organisation establish before submitting the change?

Only the preferred wording in one national language The applicable procedure, RMS and CMS structure, current product information and scientific justification Whether the RMS can be bypassed because the change concerns safety Whether the product can be converted automatically to a centralised authorisation

Question 5 of 10 A company applies for authorisation of a medicine that has not previously been authorised in the EU in several Member States. Which procedure and regulatory arrangement best fit this situation?

MRP, with an existing national authorisation serving as the basis for recognition DCP, with one Member State acting as RMS and the others as CMSs Centralised procedure, with CMDh acting as scientific assessor Referral procedure, with PRAC automatically acting as RMS

Question 6 of 10 Which situation most clearly distinguishes the RMS from EMA and CHMP?

The RMS leads an MRP or DCP as a national authority, whereas EMA and CHMP operate within the centralised and specified Union-level procedures The RMS and CHMP are interchangeable names for the same assessment body EMA and CHMP only perform administrative tasks, while the RMS performs all scientific work The RMS is a permanent committee within EMA

Question 7 of 10 Which combination best represents evidence that may be integrated into a safety assessment?

Only the number of spontaneous reports and the applicant's commercial forecast Clinical cases, temporal relationship, alternative explanations, background incidence, epidemiology and biological evidence Only a plausible mechanism and a single severe case Only the wording proposed for the package leaflet

Question 8 of 10 Which description most accurately captures the institutional status of the RMS?

A European Union agency that grants one Union-wide marketing authorisation A national competent authority leading and coordinating a specific MRP or DCP A committee of the European Parliament responsible for medicines legislation The marketing authorisation holder's regulatory representative

Question 9 of 10 Which action best demonstrates effective QPPV oversight of an RMS-related safety issue?

The QPPV replaces Regulatory Affairs in all communications with the RMS The QPPV identifies affected products, Member States, current product information, RMS and potential regulatory implications The QPPV assumes that the RMS automatically manages all pharmacovigilance obligations The QPPV limits review to the Member State where the adverse event was first reported

Question 10 of 10 What is the defining starting point of an MRP?

An existing marketing authorisation in one Member State A prior CHMP positive opinion A new application with no EU authorisation anywhere A CMDh decision requiring national authorisations

QPPV.com

Knowledge Assessment: Reference Member State (RMS) in EU Regulatory Affairs

Cookie Settings